The ability of long non-coding RNA IGFBP4-1 to modulate Cellular Metabolism is a potential breakthrough in Lung Cancer Therapy

Soham Datta1,2, Binyao Yang2, Jiachun Lu1,2 *

1The State Key Lab of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, 151 Yanjiangxi Road, Guangzhou, 510120, China
2The School of Public Health, The Institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, 510182, China

Article Info

Article Notes
Received: December 08, 2017
Accepted: January 18, 2018

*Correspondence:
Dr. Jiachun Lu, The State Key Lab of Respiratory Disease; The First Affiliated Hospital, The School of Public Health, The Institute for Chemical Carcinogenesis, Collaborative Innovation Center for Environmental Toxicity, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou 510182, P.R. China; Telephone: 86-20-37103043; Fax: 86-20-37103099, E-mail: jcLu@gzhmu.edu.cn

© 2017 Lu J. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.

ABSTRACT

Lung cancer being one of the leading causes of cancer-related deaths around the world has significantly added to the global burden of disease. Late diagnosis, unavailability of definitive treatment and an unclear pathophysiological mechanism behind the role of various genes expressed in lung cancer make it a challenge that needs new techniques and better understanding of the underlying pathology and role of genetics. Long non-coding RNAs, once considered insignificant, are now being elucidated to have major roles to play in the regulation and development of carcinogenesis. In this review, the ability of a lncRNA, lncRNA IGFBP4-1 to modulate cellular metabolic processes, eventually affecting lung cancer progression and consequently being a potential biomarker for lung cancer diagnosis has been discussed.

Introduction

In recent studies, it has been shown that long non-coding RNAs (lncRNA) can regulate and develop cancer progression by facilitating cell growth and proliferation. In our recent study, "Overexpression of lncRNA IGFBP4–1 reprograms energy metabolism to promote lung cancer progression"1, an attempt has been made to elucidate the connection between lncRNA and cell metabolism in tumour cells which could be a new thinking not only in exploring a valuable biomarker in early diagnosis but also in being a potential path in lung cancer therapy.

Global Burden of Lung Cancer

Cancer has been shown to be one of the leading causes of mortality and morbidity around the world. There have been around 14 million new cases reported in the year 2012 and lung cancer deaths have amounted to 19 percent of all mortalities caused by any cancer2. As per the World Cancer Report published in 2017, lung cancer is one of the leading causes of mortality around the world and has caused 1.69 million deaths in 20153. The clinical treatment of lung cancer has developed in leaps and bounds especially with the advent of precision medicine, but the overall survival rate has still not improved significantly due to the paucity of cancer biomarkers in early diagnosis and as a result leading to a late diagnosis of the disease often involved with lymph nodes involvement and metastasis into other organs.
Role of IncRNAs

The role of IncRNA and its mutation and aberrant expression causing physiological changes such as cell growth and apoptosis, and pathological changes such as metastasis and invasion, consequently contributing to development and promotion of tumour cells in carcinogenesis has been illustrated in recent studies4-6. The communication between proteins associated with various IncRNAs had distinct molecular processes and the IncRNAs were found to have functional interrelation with the sense genes4. There was significant difference in the IncRNA expression in normal tissues and in non-small lung cancer tissues illustrating the possible role of specific IncRNA screening tests6. These IncRNAs have been shown to regulate metabolism and metastasis in tumour cells thus providing evidence that they are potential biomarkers. Similarly, IncRNA insulin-like growth factor receptor binding protein (IGFBP4-1) has been shown to influence cell metabolism and proliferate lung cancer.

Role of IncRNA-IGFBP4-1

Lnc-IGFBP4-1 is located in the upstream section of IGFBP4 gene and these proteins are known to be regulation factors involved in the metabolism of growth cancer cells by competing with insulin-like growth factor receptor(IGFR), combining with insulin-like growth factor(IGF) and as a result, modulating the physiological functions of the IGF9. There is evidence that Inc-IGFBP4–1 has been significantly overexpressed in lung cancer tissues in respect to adjacent normal histological tissues and the high localization of Inc-IGFBP4–1 in the nucleus of cancer cells hints at its transcriptional regulation ability. The upregulation of Inc-IGFBP4–1 increased the cell proliferation ability significantly in lung cancer cell lines, and there is proof of increased migration and invasion of cancer cells with an overexpression of Inc-IGFBP4–1. Similarly, downregulation of Inc-IGFBP4–1 decreased cell migration and invasion and increased apoptosis of lung cancer cells pointing to the influence of this IncRNA in lung cancer cell growth and proliferation in vitro and in vivo10,11. The energy (ATP) levels were significantly elevated in cancer cells that had an overexpression of Inc-IGFBP4–1, the increase in metabolic enzymes in upregulated Inc-IGFBP4–1 tumour cells and vice versa, thus indicating the role Inc-IGFBP4–1 plays at a transcriptional level in modulating lung cancer cell metabolism1 which is a hallmark of cancer.

Potential of Inc-IGFBP4-1 in Lung Cancer therapy

Long noncoding RNA Inc-IGFBP4–1 seems certain to be a major regulator in the development, progression and spread of lung cancer by promoting cell growth and inhibiting apoptosis, however, there are a few limitations. Unfortunately, there is still no comprehensive understanding of the mechanisms behind how Inc-IGFBP4–1 modulates the lung tumour cells at a transcriptional level to change their pathophysiological properties to the extent that it affects their metabolism and growth. There is further room for research and investigation on IncRNAs like Inc-IGFBP4–1 and their associated oncogenes which have connections with tumour promoting activities. Once these molecular mechanisms are thoroughly understood, and there is prognostic review knowledge of Inc-IGFBP4–1, there is clear indication that this IncRNA will not only be an essential biomarker in early lung cancer diagnosis but also an encouraging nouveau point of target for lung cancer therapeutics.

Conflict of interest

The authors have declared no conflicts of interest.

Acknowledgments

This study was supported by the National Key R&D Projects (2016YFC0903700), the National Natural Science Foundation of China (No.81473040, 81673267,81273149, 81402753, 81672303, 81602289) and Yangcheng Scholar Grants (1201541589).

References